Effect of lamivudine treatment on plasma levels of transforming growth factor &beta;1, tissue inhibitor of metalloproteinases-1 and metalloproteinase-1 in patients with chronic hepatitis B

doi:10.3748/wjg.v10.i18.2661

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 18

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2951)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-5) series.

Item

Count

PDF

287

HTML

2279

Figures (1-4)

183

Tables (1-5)

202

Sum=2951

Sep 15, 2004 (publication date) through Nov 12, 2024

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Viral Hepatitis

World J Gastroenterol. Sep 15, 2004; 10(18): 2661-2665
Published online Sep 15, 2004. doi: 10.3748/wjg.v10.i18.2661

Table 3 Values of scored degree of hepatic inflammation and fibrosis in liver biopsy specimens obtained from patients before and after lamivudine treatment (mean ± SE)

	Before the treatment	After the treatment
Portal inflammation	2.6 ± 0.1	2.5 ± 0.2
Lobular inflammation	1.9 ± 0.1	1.8 ± 0.1
Fibrosis	2.0 ± 0.2	1.8 ± 0.2

Citation: Flisiak R, Al-Kadasi H, Jaroszewicz J, Prokopowicz D, Flisiak I. Effect of lamivudine treatment on plasma levels of transforming growth factor β₁, tissue inhibitor of metalloproteinases-1 and metalloproteinase-1 in patients with chronic hepatitis B. World J Gastroenterol 2004; 10(18): 2661-2665
URL: https://www.wjgnet.com/1007-9327/full/v10/i18/2661.htm
DOI: https://dx.doi.org/10.3748/wjg.v10.i18.2661